CIK: 0001834239
Total reported value
$1.0B
Reporting period: 2026-03-31 · Number of holdings: 5
EQT Fund Management S.a r.l. disclosed 5 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.0B and a quarterly turnover rate of 31.8%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "E"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim WAY
0.0% -$215.0M
Add OCS
0.0% $39.1M
Add EVMN
0.0% $28.9M
Add PHVS
0.0% $1.7M
New buy AGMB
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | WAY | Waystar Holding CORP | Stock-Other | 58.77% | -14.51% | — | |
| 2 | OCS | Oculis Holding AG | Stock-Other | 15.37% | +4.77% | — | |
| 3 | EVMN | Evommune INC | Stock-Other | 11.10% | +3.51% | — | |
| 4 | PHVS | Pharvaris N.V. | Stock-Other | 9.48% | +0.93% | — | |
| 5 | AGMB | Agomab Therapeutics NV | Stock-Other | 5.28% | +5.28% | NEW |
Performance for Q3 2026
-2.6%
Performance Last 4 Quarters
-9.4%
Based on 85% of reported portfolio value with available pricing
Not enough sector-mapped data yet
EQT Fund Management S.a r.l.'s most significant position changes for 2026-03-31: New buy: Agomab Therapeutics NV (AGMB).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | OCS | Oculis Holding AG | +4.8% | — | Unchanged |
| 2 | EVMN | Evommune INC | +3.5% | — | Unchanged |
| 3 | PHVS | Pharvaris N.V. | +0.9% | — | Unchanged |
| 4 | WAY | Waystar Holding CORP | -14.5% | — | Unchanged |
| 5 | AGMB | Agomab Therapeutics NV | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-14 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-11 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-10-30 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-09 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-04-19 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-06 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-07-21 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001673633
Total reported value
$1.0B
454 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001740858
Total reported value
$1.0B
3 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0000791490
Total reported value
$1.0B
293 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001757283
Total reported value
$176.9M
7 stks
2026-03-31
2 of the top 5 holdings overlap, including Evommune INC
CIK 0001782539
Total reported value
$121.3M
24 stks
2026-03-31
2 of the top 5 holdings overlap, including Evommune INC
CIK 0001844645
Total reported value
$279.8M
13 stks
2026-03-31
2 of the top 5 holdings overlap, including Oculis Holding AG